Skip to main navigation
  • Contact Us
  • Global
    • International
    • Canada
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands
    • Spain
Amicus Therapeutics
  • About Amicus
    • About Amicus
    • Executive Chairman’s Welcome
    • Belief Statement
    • Our Founding Legacy
    • Leadership
    • Contact Us
    • Message from the President and CEO
  • Patient Advocacy
    • Patient Advocacy
    • Rare Stories
    • Patient Advisory Boards
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Programs & Pipeline
    • Our Pipeline
    • Fabry Disease
    • Pompe Disease
    • Batten Disease
    • Additional Preclinical Programs
    • Clinical Trials
    • Global Research Center
  • Products
    • Products & Services
    • Galafold®(migalastat)
    • Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat)
    • AMICUS ASSIST®
  • Responsibility
    • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Investors & Media
    • Investor Relations
    • Senior Management Team
    • Board of Directors
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports and Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Contact Us
    • Sign Up for Email Alerts
  • Careers
    • Careers
    • Overview
    • Search

Investors

Press Releases

Press Releases

December 5, 2023
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
November 8, 2023
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 1, 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
October 27, 2023
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 3, 2023
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 2, 2023
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
September 28, 2023
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 1, 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
August 29, 2023
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 21, 2023
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
  • About Amicus
    • Executive Chairman’s Welcome
    • Message from the President and CEO
    • Leadership
    • Our Founding Legacy
    • Belief Statement
    • Contact Us
  • Patient Advocacy
    • Rare Stories
    • Patient Advisory Boards
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Pipeline
    • Our Programs
    • Clinical Trials
  • Our Products
    • Overview
    • Amicus Assist™
  • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports & Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Featured Coverage
  • Careers
    • Overview
    • Search
  • Social Media
    • Twitter
    • YouTube
    • LinkedIn
Copyright © 2023 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119
  • Cookies Statement
  • Terms of Use
  • Privacy Notice
  • Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional